11 results about "Lymphatic/immune" patented technology

The present application relates to the field of pet feed, and discloses a maintenance ration formula for improving the smoothness of dog hair. The formula comprises base ration particles and lipid microcapsules attached to the surface of the base ration particles; the lipid microcapsules encapsulate a core material composed of essential fatty acids and ceramides, have a double-layer wall material structure, and the outer layer is acid-resistant plant gum and the inner layer is lipase-sensitive phospholipid; the microcapsules are attached to the surface of the puffed base ration by low-temperature vacuum spraying. The present application makes the microcapsules resistant to gastric acid and releases the core material under the action of duodenal lipase, targets and enriches in sebaceous glands through the lymphatic system, solves the problems of low lipid delivery conversion rate and insufficient substrate of sebaceous glands, improves the proportion of sebaceous gland ceramides, and reduces the hair friction coefficient.

To provide a small, easy-to-handle portable biological information observation device. [Solution] A portable bio-information observation device according to one embodiment of the present invention is a portable bio-information observation system comprising at least an irradiation device for irradiating the lymphatic system and / or blood vessels as the part to be observed with photon energy, an imaging device for imaging the visualized part to be observed, a display device, and an operation unit, wherein the system comprises a main body having the irradiation device, the imaging device, and the display device, the main body having a photon energy emission unit and an imaging unit on one side of its opposing surface, a display unit on the other side of the opposing surface, and an illumination control unit for controlling the visualization light of the illumination device, the illumination control unit controlling the irradiation device for irradiating the photon energy to have a wavelength, brightness, and brightness distribution set according to the visualization conditions of the part to be observed, based on a command from the operation unit.

This invention relates to the interdisciplinary field of biomedicine and molecular imaging, specifically a novel magnetic resonance imaging contrast agent, its preparation method, and its application. The contrast agent uses thymosin α1 as the parent compound, linked with three identical substituents R, where R are metal chelate groups. These metal chelate groups are formed by coordination of a chelating agent and a metal ion; the chelating agent can be diethylenetriaminepentaacetic acid, etc., and the metal ion can be selected from gadolinium, manganese, and iron. The preparation method of the contrast agent includes: activating the chelating agent and grafting it onto thymosin α1 to form a chelate precursor; and coordinating the chelate precursor with a metal ion. The contrast agent prepared by this invention exhibits a significant T1 enhancement effect, lymphoselectivity, and reduced concomitant venous contamination; detection results show that it has excellent lymphatic system visualization capabilities in in vivo animal imaging, providing a prospective reference for replacing existing contrast agents.

A lymphatic system examination device includes a main body portion including a placement portion on which a subject in which a fluorescent dye is injected into a lymphatic system stands, and configured to position a lower body of the subject in an imaging region on the placement portion; an illumination unit configured to irradiate the lower body with excitation light; and an imaging unit configured to detect fluorescence emitted from the lower body in response to irradiation of the excitation light. The placement portion is provided with a positioning portion that indicates a standing position of the subject.

The present disclosure provides an apparel for facilitating a lymphatic therapy in relation to a user body. Further, the apparel may include an apparel layer which may be configured to be positioned on the user body associated with a user. Further, the apparel layer includes a compression layer which may be configured for facilitating a compression of the apparel in relation to the user body. Further, the compression results in the lymphatic therapy in relation to a lymphatic system comprised in the user body. Further, the compression layer further includes a three dimensional pattern which may be configured for facilitating a nano-massage associated with the user body. Further, the nano-massage corresponds to a micro-level stimulation of the user body. Further, the lymphatic therapy may be further based on the nano massage.

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

The presently disclosed subject matter relates to methods and devices for decompressing the lymphatic system. In particular, the present disclosure provides devices for actively or passively decompressing the lymphatic system and methods of their use and deployment within a subject. In certain non-limiting embodiments, a device of the present disclosure can include a pump for actively transferring lymph fluid from the lymphatic fluid into the venous system.

Disclosed herein is a method of treating neurodegenerative diseases involving accumulation of abnormal proteins in the central nervous system (CNS) of a user. The method includes utilizing an intraoral device to apply photobiomodulation and vibration to specific points on hard and soft palates of the user to stimulate the user's glymphatic system and decongest hyperphosphorylated tau and amyloid proteins and toxins, and simultaneously with the utilization of the intraoral device, applying a transcranial device to exert vasopneumatic compression and photobiomodulation on the user's head and neck to stimulate the user's lymphatic system and enhance the flow of lymphatic fluid towards the subclavian lymphatic pathway.

The application discloses a method, equipment, medium and program product for evaluating the treatment effect of levosimendan on sepsis-related encephalopathy. The method is based on brain blood flow data, clearance rate data of the glial lymphatic system and / or expression data of AQP4 to evaluate the treatment effect of levosimendan on sepsis-related encephalopathy, and the method can effectively evaluate the curative effect of levosimendan on sepsis-related encephalopathy, thereby providing further guidance for optimizing the treatment of levosimendan on sepsis-related encephalopathy and research, and being beneficial to guiding clinicians to formulate individualized treatment plans for patients.

The application discloses a method and system for evaluating the risk of neurodegenerative disease progression. The method comprises: obtaining multi-modal brain image data and all-night sleep electroencephalogram data of the same subject; calculating brain lymphatic indicators reflecting the brain lymphatic system clearance function and sleep coupling indicators reflecting the coupling characteristics between slow wave oscillation and theta rhythm or spindle wave in non-rapid eye movement sleep period; inputting the above two types of indicators into a pre-trained risk prediction model to obtain the risk evaluation result of the subject. The pre-trained model is based on historical population data, and the brain lymphatic and sleep coupling indicators pair with significant intermediary correlation with cognitive decline is screened out through intermediary analysis as correlation characteristics, and the model is trained using these characteristics. The application significantly improves the accuracy and interpretability of disease progression prediction through mechanism-oriented feature fusion, providing a new quantitative tool for early warning and individualized intervention of neurodegenerative diseases.

The embodiment of the present application relates to a kind of method and device based on early Alzheimer's disease prediction of lymphoid system characteristics, the method comprises: gathering original sample set, based on 3D-UNet model, first segmentation model is constructed, based on MLP model, first prediction model is constructed;Based on original sample set, first, second data set is constructed;First segmentation model is trained based on first data set;First prediction model is trained based on second data set;After model training ends, the brain DTI image and brain 3D-T2 weighted image of subject are received, and according to brain DTI image, left and right brain ALPS index analysis is carried out based on DTI-ALPS technique, and based on first segmentation model, semantic segmentation is carried out to brain 3D-T2 weighted image, and according to segmentation result, four brain area perivascular space volume fraction analysis is carried out, and using first prediction model, according to two kinds of analysis results, prediction is carried out.The present application can improve processing efficiency, improve prediction accuracy.